Induction of apoptosis and G2/M cell cycle arrest by oridonin in human gastric cancer BGC-823 cells

Abstract

Abstract:

Aim To investigate in vitro apoptosis-induction effects of oridonin on gastric tumor cells BGC-823 and its effects on cell cycle, mitochondrial membrane potential and intracellular Ca²⁺ to shed light on the mode of its anticancer action. Methods The MTT method was used to investigate the inhibitory effect of oridonin on BGC-823 cells. The apoptosis-induction effect was evaluated by confocal laser microscopy and flow cytometry. The change of mitochondrial membrane potential and the increase of intracellular Ca²⁺ were assessed by fluorescence probe rhodamine123 and Fluo 3-AM, respectively, with flow cytometry. The expression of apoptosis and cell cycle related proteins was studied using western blotting. Results Oridonin inhibited BGC-823 cells growth with IC₅₀ of 22.21 μmol·L^-1. It induced apoptosis in a dose-dependent manner. In addition, it decreased mitochondria membrane potential, increased intracellular Ca²⁺, and activated pro-caspase 3. BGC-823 cells were arrested in G2/M cell cycle phase with lower expression of cyclin A protein. The up-regulation of p53 was observed before apoptosis and cell cycle arrest occurred. Conclusion Oridonin inhibits the proliferation of BGC-823 cells through G2/M cell cycle arrest and apoptosis induction, which is mediated by influx of Ca²⁺, up-regulation of p53, activation of caspase-3, and down-regulation of cyclin A.

Key words: Oridonin, Oridonin, Human gastric cancer, Human gastric cancer, Apoptosis, Apoptosis, Cell cycle arrest, Cell cycle arrest, p53, p53, Cyclin A, Cyclin A

CLC Number:

R965

Supporting:

Jian Han, Min Ye, Xue Qiao, Wan-Ying Wu, Gui-Qin Qu, De-An Guo^*. Induction of apoptosis and G₂/M cell cycle arrest by oridonin in human gastric cancer BGC-823 cells[J]. .

References

[1] Meade-Tollin, L.C.; Wijeratne, E.M.; Cooper, D.; Guild, M.; Jon, E.; Fritz, A.; Zhou, G.X.; Whitesell, L.; Liang, J.Y. J. Nat. Prod. 2004, 67: 2–4.
[2] Sartippour, M.R.; Seeram, N.P.; Heber, D; Hardy, M. Int. J. Oncol. 2005, 26: 121–127.
[3] Liu, J.J.; Wu, X.Y.; Peng, J; Pan, X.L.; Lu, H.L. Ann. Hematol. 2004, 83: 691–695.
[4] Liu, J.J.; Huang, R.W.; Lin, D.J.; Wu, X.J. Neoplasma. 2005, 52(3): 225–230.
[5] Zhang, C.L.; Wu, L.J.; Tashiro, S.; Onodera, S.; Ikajima, T. J. Asian. Nat. Prod. Res. 2004, 6(2): 127–138.
[6] Zhang, C.L.; Wu, L.J.; Tashiro, S.; Onodera, S.; Ikajima, T. Acta Pharmacol. Sin. 2004, 25(5): 691–698.
[7] Zhang, J.F.; Liu, J.J.; Lu, M.Q. Chin. Tradit. Herb. Drugs. 2006, 37(10): 1517–1521.
[8] Bai, J.; Rodriguez, A.M.; Melendez, J.A. J. Biol. Chem. 1999, 274: 26217–26224.
[9] Bradford, M.M. Anal. Biochem. 1976, 72: 248–254.
[10] Lorne, J.H.; Perwez, S.H.; Curtis, C.H. Trends Pharmacol. Sci. 2004, 25(4): 177–181.
[11] Fujita, E.; Nagao, Y.; Node, M.; Kaneko, K.; Nakazawa, S.; Kuroda, H. Experientia.1976, 32(2): 203–206.
[12] Ikezoe, T.; Chen, S.S.; Tong, X.J. Int. J. Oncol. 2003, 23 (4): 1187–1189.
[13] Chen, S.; Gao, J.; Halicka, H.D.; Huang, X.; Traganous, F.; Darzynkiewicz, Z. Int. J. Oncol. 2005, 26 (3): 579–588.
[14] Ikezoe, T.; Yang, Y.; Bandobashi, K.; Saito, T.; Takemoto, S. Mol. Cancer. Ther. 2005, 4 (4): 578–586.
[15] Hsieh, T.C.; Wijeratne, E.K.; Liang, J.Y.; Gunatilaka, A.L.; Wu, J.M. Biochem. Biophys. Res. Commun. 2005, 337(1): 224–231.
[16] Green, D.R.; Reed, J.C. Science. 1998, 281(5381): 1309–1312.
[17] Robertson, J.D.; Orrenius, S. Crit. Rev. Toxicol. 2000, 30: 609–627.
[18] Liu, J.J.; Huang, R.W.; Lin, D.J.; Wu, X.J. Leuk Lymphoma. 2005, 46(4): 593–597.
[19] Ren, K.K.; Wang, H.Z.; Xie, L.P.; Chen, D.W.; Liu, X. J. Ethnopharmacol. 2006, 103(2): 176–180.
[20] Zhang, T.M.; Shou, M.G.; Wang, M.Y. Acta Pharmacol. Sin. 1986, 7(5): 457–460.
[21] Bratton, S.B.; Cohen, G.M. Trends Pharmacol. Sci. 2001, 22: 306–315.
[22] Xue, H.W.; Pan, X.L.; Yang, S.J. J. Shandong Univ. (Health Sciences). 2003, 43(4): 336–339.
[23] Liu, J.S.; Xia, D.M.; Pan, H.Z. Signal of cell and its regulation: collection of modern biology and medicine; Joint Press of Beijing Medical University and Peking Union Medical University: Beijing, China, 1999, 334–344.
[24] Dumont, A.; Hehner, S.P.; Horgmann, T.G. Oncogene. 1999, 18: 747–757.
[25] Fall, C.P.; Bennett, J.P. Jr. Biochim. Biophy. Acta. 1999, 1410: 77–84.

Induction of apoptosis and G₂/M cell cycle arrest by oridonin in human gastric cancer BGC-823 cells

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Fan Wang, Ruili Li, Wenjun Wang, Xiaoyan Zhou, Meiyou Liu, Jinyi Zhao, Aidong Wen, Jingwen Wang, Yanyan Jia. α-Boswellic acid ameliorates acute kidney injury by inhibiting the TLR4-mediated inflammatory pathway [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(7): 539-550.
[2]	Limei Yang, Liman Wang, Xuhui Huang, Jie Zhuang. Warfarin affects the proliferation and apoptosis of lung cancer cells by regulating the Gas6/Axl/PI3K/Akt/NF-κB pathway [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(3): 190-199.
[3]	Peijie Chen, Yuntian Zhang. PTP1B restrains the apoptosis of activated hepatic stellate cells (HSCs) induced by TRAIL during the resolution of liver fibrosis [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(11): 867-880.
[4]	Wuyinxiao Zheng, Haiping Li, Laichun Luo, Chunling Hu, Pengtao You. PI3K/AKT/mTOR pathway inhibition and miR-210-mediated suppression of Atg7 promote autophagy in TOPC-induced apoptosis of H1975 cells [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(11): 881-892.
[5]	Ziyi Wang, Xiaoyan Liu, Yuanjun Zhu, Ye Liu, Pingping Zhang, Yinye Wang. The protective effect of W026B on global cerebral ischemia/reperfusion injury model in rats [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(2): 108-116.
[6]	Chunyang Han, Taotao Sun, Guangtai Fan, Yawei Liu, Cuiyan Liu. Protective effects of Polygonatum sibiricum against CCl4-induced acute liver injury in rats through oxidative stress and mitochondrial apoptotic pathways [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(4): 306-318.
[7]	Kexiang Gao, Xiaoyan Liu, Yuanjun Zhu, Ye Liu, Yinye Wang. The influence of B55γ on the neuroprotective effect of W026B in t-MCAO mice [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(10): 711-718.
[8]	Jianwei Gao, Feng Ye. Curcumin inhibits inflammatory cytokine transcription via the apoptosis pathway in THP-1 cells [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(2): 100-113.
[9]	Kuai Yu, Ruyi Li, Yuanjun Zhu, Xiaoyan Liu, Yinye Wang. Engineering the protein targeting two pathways of cerebral ischemia reperfusion injury provides better neuroprotective effect than targeting one pathway [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(11): 760-769.
[10]	Xu Quan, Caihong Gu, Feng Yan, Yaoyao Gao, Lin Chen, Rong Wei, Bingchun Yan, Rong Hu. Porcine placental peptides improve neuroblast proliferation and differentiation via enhancement of TrkB and BDNF levels in D-glatacose-induced mouse aging model [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(10): 739-748.
[11]	Li Lei, Yu Chen, Simin Yang, Xiangbao Meng, Siwang Yu. A novel aza-naphthoquinone inhibits tumor growth by inducing apoptosis [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(9): 600-607.
[12]	Yuqing Meng, Lichao Wang, Yan Li, Jinyang Song, Zhiyong Du, Chun Li, Yong Jiang, Pengfei Tu, Xiaoyu Guo. Cardioprotective effects of combination of notoginseng total saponins and safflower total flavonoids against myocardial infarction in rats [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(2): 116-122.
[13]	Shasha Ji, Yun Lei, Xiaotian Huang, Zhiqin Gao. Protective effects of β-dihydroagarofuran-type sesquiterpene against Aβ25-35-induced neuronal apoptosis and oxidative damage [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(8): 582-589.
[14]	Hongjun Xie, Lei Liu, Fan Zeng, Limin Mu, Yao Zhao, Yan Yan, Yingjie Hu, Jiashuan Wu, Yingzi Bu, Jingying Zhang, Wanliang Lu. Efficacy and mechanism of antiresistant vinorelbine liposomes in treating resistant breast cancer cells [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(7): 489-501.
[15]	Yao Zhao, Jingying Zhang, Yingjie Hu, Jiashuan Wu, Yingzi Bu, Wanliang Lu. Augmented efficacy and the mechanism of a combined use of daunorubicin with rofecoxib in treatment of triple-negative breast cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(6): 438-447.